Dr. Steven Green -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Steven Green, a Dermatology physician based in Houston, TX. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Steven Green has received $7,551.52 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Steven Green has received a total of $7,551.52 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $7,551.52 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Steven Green's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Speaking & Education$7,551.52Promotional speaking, CME events, and educational presentations

The largest payment category for Dr. Steven Green is Speaking & Education, accounting for 100% ($7,551.52) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Steven Green. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Johnson & Johnson$7,551.521

Dr. Steven Green has a financial relationship with Johnson & Johnson, receiving $7,551.52 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

Drugs and Medical Devices Referenced in Payments

The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Steven Green. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.

The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Steven Green's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Dr. Steven Green, a dermatologist in Houston, TX, has received a total of $7,551.52 in pharmaceutical payments from a single source, Johnson & Johnson, for a speaking engagement scheduled for October 9, 2025. This payment volume is exceptionally low when compared to the average for dermatologists. The vast majority of dermatologists engage in numerous professional interactions with pharmaceutical companies, often involving consulting, research, speaking, and educational events. The total payment received by Dr. Green is a single, future-dated speaking fee. This suggests a minimal, if any, ongoing financial relationship with the pharmaceutical industry. The payment type is exclusively for speaking, indicating a specific engagement rather than a broad consulting or research collaboration. This pattern does not suggest routine professional activity that would typically involve multiple interactions and varied payment types over time. Instead, it points to a singular, scheduled event. For patients, understanding these payments is crucial for maintaining trust and informed decision-making. While pharmaceutical payments can facilitate medical education and research, they can also introduce potential conflicts of interest. In Dr. Green's case, the limited nature of the payment is unlikely to raise significant concerns about influence on his clinical practice. However, patients should always feel empowered to discuss any financial relationships their doctors may have with drug companies and understand how these relationships might inform treatment recommendations. Transparency in these matters allows patients to engage in more open dialogue with their healthcare providers, ensuring that treatment decisions are based solely on their individual health needs and the best available medical evidence.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Steven Green is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

When considering your doctor's financial relationships with pharmaceutical companies, it's important to maintain perspective. Small payments for speaking or consulting, especially when infrequent and disclosed, are often part of professional development and education. However, substantial or frequent payments, particularly those involving multiple companies or varied services like research and consulting, might warrant closer examination. At your next appointment, consider asking your doctor: 'Are you involved in any consulting or speaking engagements with pharmaceutical companies that make medications I might be prescribed?' or 'How do you stay updated on the latest treatments and medications?' Pay attention to whether your doctor seems overly enthusiastic about a particular drug or class of drugs, especially if they have recently received payments related to them. Red flags include a doctor pushing a specific, expensive medication without a clear rationale or dismissing alternative, less costly treatments. It's normal for doctors to have relationships with drug companies, as these interactions can bring valuable information about new therapies. The concern arises when these relationships appear to influence prescribing decisions away from the patient's best interest. You can evaluate your doctor's prescribing patterns by researching medication costs and alternatives, and by seeking second opinions if you have concerns.

Peer Comparison: How Dr. Steven Green Compares to Other Dermatology Physicians

The average total payment received by dermatologists from pharmaceutical companies is significantly higher than Dr. Green's $7,551.52. While specific averages vary, many dermatologists receive payments that can range from tens of thousands to hundreds of thousands of dollars annually, often spread across multiple companies and payment types. Dr. Green's single payment places him at the extreme low end of the payment spectrum for his specialty, indicating a minimal financial engagement with the pharmaceutical industry compared to his peers.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Steven Green in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Johnson & Johnson$7,551.52speakingRevlimid2025-10-09Not Assessed

Frequently Asked Questions About Dr. Steven Green's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

Is Dr. Steven Green taking too much pharma money?

Dr. Steven Green has received a single payment of $7,551.52 from Johnson & Johnson for a future speaking engagement. This amount is exceptionally low compared to the average financial engagement between dermatologists and pharmaceutical companies. Most dermatologists receive significantly more in payments, often spread across multiple companies and types of services. Therefore, based on the available data, Dr. Green's payment volume is minimal and does not suggest he is taking excessive money from pharmaceutical companies.

What pharma companies pay Dr. Steven Green?

Dr. Steven Green has received payments exclusively from Johnson & Johnson. The total amount from this company is $7,551.52, designated for a speaking engagement scheduled for October 9, 2025.

Should I switch doctors because of pharma payments?

Switching doctors solely based on this payment data is likely unnecessary. Dr. Green's payment is a single, future speaking fee, which is a very small financial interaction compared to industry norms for dermatologists. Concerns about switching doctors typically arise with patterns of frequent, substantial payments across various services (consulting, research, etc.) that might suggest a conflict of interest. If you have specific concerns about your care or trust, discuss them directly with Dr. Green. Transparency is key, and his limited engagement here is unlikely to be a primary reason for concern.

What kinds of payments does this doctor receive?

Dr. Green's payment profile consists solely of a speaking fee. He has received no payments for consulting, meals, travel, research, or ownership interests from pharmaceutical companies based on the provided data. This indicates a singular, specific engagement rather than a broad range of professional services.

How do these payments compare to other Dermatology?

Dr. Green's total payment of $7,551.52 is substantially lower than the average for dermatologists. While many dermatologists receive payments totaling tens or hundreds of thousands of dollars annually from various pharmaceutical companies for a range of services, his profile shows minimal financial engagement, limited to one future speaking engagement.

Do pharma payments affect prescribing quality?

Research suggests that even small payments can influence physician prescribing habits, potentially leading to increased prescription of the paying company's drugs. However, the extent of this influence varies greatly. For Dr. Green, the single speaking fee is unlikely to have a significant impact on his overall prescribing quality, especially given its limited nature and future date. It's more about the pattern and volume of payments that raise concerns about potential bias.

How can I verify this payment data?

You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Visit the official CMS Open Payments website, search for 'Dr. Steven Green' and input his National Provider Identifier (NPI) number, which is 1583725797. The database provides detailed records of payments made by pharmaceutical and medical device companies to physicians and teaching hospitals.

Understanding This Doctor Payment Report

This transparency report for Dr. Steven Green is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Steven Green's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Steven Green and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.